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Background: Physical activity (PA), physical fitness (PF), and even a few sedentary behaviors (SB) are strongly
and independently linked to improved survival rate. However, key questions remain: what are the physiological
interrelationships between SB, PA, and PF? How should we differently emphasize promoting PA, increasing PF
with exercise, and decreasing SB among other prevention measures? What are the interrelationships of both
PA and SB levels with drug treatment efficacy?
Methods: To address these questions we developed an integrated patient-centric model combining physiology
with epidemiological evidence to characterize the individual risk attached to PA level, PF, and SB. Epidemiological
data were collected by extensive literature review.
Results: Nine meta-analyses, 198 cohort studies (3.8 million people), and 13 controlled trials were reviewed.1. A high level of SB induces chronic stress and increases the risk of both chronic disease and mortality.
2. Vigorous PA increases PF and physiological reserve, thereby improving survival rate. This effect is notmediated by improved
traditional risk factors.
The risk for most individuals is a mix of high SB, low to mild PA, and low to mild PF.
This model can improve the individualized prescription of PAmodalities. Furthermore, the benefit of treatments
such as statins or beta-blockers can be cancelled out if a decrease in PA or an increase in SB is induced by drug
related side effects.
Conclusions: To improve patient management both types of therapeutic interventions and dose should be care-
fully chosen for each individual in order to maintain/increase PA level while decreasing SB.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
The worldwide epidemic of low physical activity (PA) [1] under-
scores the need for physicians to consider PA a main component of
their patients' risk. Epidemiological studies have consistently shown
that both a high level of PA and a high level of physical fitness (PF) are
strongly linked to improved survival rate. Five days per week of at
least 30 min of moderate-intensity PA is recommended for adults [2].
Both American and European guidelines on cardiovascular diseaserancilien, 116 Boulevard Jean
haransonney).
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card.2013.11.012prevention recommendmeasuring PF by exercise testing for risk assess-
ment [3,4]. Finally, a recent European set of recommendations high-
lights the importance of characteristics and modalities of PA and
exercise for cardiovascular health in the general population [5] and in
individuals with either CV risk factors [6] or CV disease [7].
However, many practical questions remain, e.g. how much should
we emphasize PA compared with other prevention measures? How
much should we promote exercise, daily PA, or less sedentary behavior
(SB)? What is the impact (if any) of drugs on PA level and how much
does it matter? Should we favor pharmacological treatment at clinical-
trial-defined optimal dose over preserving or increasing PA level? Sur-
prisingly, PA is usually superseded in priority order by advising pharma-
cological treatment and nutrition [8] despite weaker evidence
supporting the association of dietary factors with mortality.
To address these practical issues we developed a patient-centric
model describing the interaction between PA, PF, SB, and an individual'sepidemiological evidence to individualized patient management, Int J
2 O.L. Charansonney et al. / International Journal of Cardiology xxx (2013) xxx–xxxrisk of prematuremortality. Relevant epidemiological evidencewas col-
lected by reviewing the literature.
2. Method
2.1. Patient-centric model: objective and requirements
Our main objective is to develop a patient-centric model which integrates epidemio-
logical evidence within a physiological approach. This model should characterize, at the
individual level, the lifetime interactions of PA, PF, and SBwithmortality risk. PF, a power-
ful risk predictor, is a fundamental physiological characteristic. PA and SB are two behav-
iors also linked to premature mortality rate. Interplay between these three components is
suspected but should be better characterized.
In order to base our model on solid epidemiological ground, we needed to review
epidemiological evidence with a particular interest in the interactions between PA, PF,
SB, and mortality rate. We used meta-analyses to quantify these interactions. However,
the strength of this quantification is limited in that meta-analyses only take into account
the common pieces of information in a limited set of studies. Furthermore, meta-
analyses only assess statistical associations between PF, PA, or SB andmortality risk. Inter-
actions between PF, PA, and SBwere only taken into account in some studies by using sta-
tistical models adjusted for PA or PF whenever measured. Therefore, we needed a more
comprehensive approach to collecting information on the interactions between PF, PA,
SB, and mortality rate. We conducted an extensive review of published reports on cohort
studies and randomized controlled trials evaluating these links (2000–2011), and also
conducted a follow-up search up to August, 2013. The objective of the extensive review
was both to evaluate the meta-analyses' results' validity in a larger set of populations
and to better understand interplay between PA, PA domains, PF, SB, and mortality rate.
The objective of the follow-up searchwas to identify new studieswhich could substantial-
ly modify the results of the previous analysis.
2.2. Literature review
Methodology of the extensive reviewwas very similar to the one required for system-
atic review, with some adaptations related to the objectives.
2.2.1. Search strategy
MEDLINE databases and the Cochrane database of systematic reviews were searched
for English language publications from 2000 to November 1, 2011. Boolean search was
used with the key words: “physical activity and/or fitness and mortality”. Citations of in-
terest were independently selected by two reviewers. We also searched the reference
list of relevant articles and reviews. Reports selected by at least one reviewerwere includ-
ed and full-texts were analyzed in-depth.
The same databases were regularly searched up to August, 2013 (follow-up search),
with review of the titles and abstracts of relevant articles.
2.2.2. Inclusion criteria
Meta-analyses assessing the strength of the links between PF, PA or SB and mortality
rate were identified and analyzed.
Prospective cohort studies and randomized studies assessing the links between either
PA or PF with mortality were selected for the extensive review. For each report selected
from the literature search, the prospective cohort on which the study was run was identi-
fied and relevant information was collected either from the report or from other related
sources such as publications or websites. Screened reports which did not provide informa-
tion onmortality rate were used for the identification of the related cohort. Other reports
on this related cohort were then searched for mortality data.
Reports identifiedwith the same search strategy during the follow-up searchwere se-
lected based on title and abstract, and on full-text article if necessary. Relevant pieces of
information from these articleswere included in thepresentwork, but not in the extensive
review.Table 1
Characteristics of meta-analyses.
1st author/year Exposure Citations identified Reports included Ind
Cooper, 2010 Walking speed 2270 28 (1.2%) 14
Davies, 2010 Exercise training (RCT) 11,561 23 (0.2%) 36
Grontved, 2011 Television viewing 1655 8 (0.5%) 26
Hamer, 2008 Walking pace 4295 18 (0.4%) 14
Kodama, 2009 PF 10,679 33 (0.3%) 10
Nocon, 2008 PF/PA 1768 33 (1.9%) 88
Samitz, 2011 PA domains 6933 80 (1.2%) 84
Taylor, 2004 Exercise training (RCT) N5000 48 (1%) 89
Woodcock, 2010 PA 6210 22 (0.4%) 97
na: not available, ns: non-significant, PA: physical activity, PF: physical fitness, RR: relative risk o
RR per 2 hours of TV viewing per day.
Please cite this article as: Charansonney OL, et al, Physical activity: From
Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2013.11.0122.2.3. Data extraction
Data were extracted from the relevant sources including selected reports and related
publications. The following data were extracted: name of first author and year, cohort
name and characteristics (country, type of population included, type of cohort), number,
age, men/women, condition/disease, PA/PA subtypes/PF/SB measurement protocols,
follow-up, type of mortality, results (semi-quantitative: positive, negative association,
neutral result, trend), gradient effect, and temporal relationships.
2.2.4. Quality assessment
The following data enable a quality assessment of each cohort: whether representa-
tive, population-based, or based on disease condition, age and sex distribution, follow-
up, type of assessment of PA, PF, or protocol used. Since there is a large discrepancy in
adjustment variables across the studies, we chose to base our semi-quantitative analysis
on age and sex adjustedmodels. However, these resultswere not provided in several stud-
ies, so in those cases we used the least adjusted model. Consistency between the several
reports on the same cohort was checked.
2.2.5. Publication bias
A formal analysis such as funnel plot is not possible because of the heterogeneity of
the results' presentation. As previously described, we tried to identify all the cohorts
which collect data on PA, PF or SB through protocol publications and web-sites.
3. Results
We first describe the relevant epidemiological information and then
lay out the model's characteristics and its usefulness for patient
management.
Ninemeta-analyses [9–17], including from 3600 to 980,000 individ-
uals, 198 cohort studies totaling 3.8 million people included in 105 co-
horts, and 12 randomized studies were analyzed in depth. Studies'
characteristics are summarized in Tables 1 & 2 (details in online supple-
mentary material). Seventy seven reports on cohort studies and one on
randomized controlled trial were identified during the follow-up
search. Full-texts of these reports were screened and results included
if relevant. The Prisma flow diagram is shown in Fig. 1.
3.1. Epidemiological studies have clearly shown that both PF and PA are
independently linked to mortality
One metabolic equivalent (MET) increase in PF is associated with a
13% decrease in the risk of premature mortality [13]. Similarly, a recent
cohort study found that a one-MET increase in PF during a 12-week
cardiac rehabilitation program is associated with a 13% reduction in
mortality [18].
Each activity which contributes to PA has an assigned energy expen-
diture (MET) which is multiplied by the time (h) spent in this activity
(Table 3). Both total PA and the various PA domains are associated
with lower mortality rate [15], and an inverse relationship between
MET-h/week and all-cause mortality rate has been found [16]. This
relation appears to be nonlinear with the benefit being greater for 11
MET-h/week of light-to-moderate PA compared with 0 MET-h (19%
reduction in the risk of premature mortality), and with a smaller incre-
mental benefit for higher levels of PA: 31MET-h/week ofmoderate PA isividuals (in mortality studies) Age at inclusion Follow-up (years) Results (RR)
,692 61– N70 3–5 0.35
47 43–72 0.5–5 0.91 (ns)
,509 N25 8 1.13*
7,063 20–93 11 0.68
2,980 37–57 1–26 0.59
3,372 na 4–20 0.59 (PF)
0.71 (PA)
4,026 56 11 0.65
40 55 1.5 0.80
7,925 38–72 5–25 0.76
f highest active group/lowest active or active/control, RCT: randomized controlled trials, *:
epidemiological evidence to individualized patient management, Int J
Table 2
Characteristics of cohort studies and randomized trials.
Studies Cohorts Individuals Age (years) Follow-up (years) Regions Characteristics at inclusion*
PF 74 25 170,000 49 14 USA: 81% Women: 13%
Korea: 11% T2DM: 5%
Europe: 7% CVD: 2%
PA 163 94 2,300,000 55 13 USA: 42% Women: 48%
Asia: 31% Elderly: 20%
Europe: 26% T2DM: 1%
CVD: 1%
Breast cancer: 1%
RCT 12 12 4,135 56 0.3–11 Women: 34%
HF: 78%
CVD: cardiovascular disease, HF: heart failure, PA: physical activity, PF: physicalfitness, RCT: randomized controlled trials, T2DM: type 2 diabetes, *: except for gender these characteristics
wer required for inclusion in specific studies.
3O.L. Charansonney et al. / International Journal of Cardiology xxx (2013) xxx–xxxassociatedwith a 24% reduction in the risk of prematuremortality com-
pared with 0 MET-h [16].
Results of the cohort studies were consistent with meta-analyses'.
All 25 cohorts which measured PF found a positive association between
PF and survival rate. PA was assessed in 94 cohorts, and only 3 small co-
horts of specific populations (chronic kidney disease, breast cancer, and
diabetes) failed to show a statistically significant association between
PA level and survival rate [19–21]. Two studies in Danish workers
found a negative association between occupational PA and survival
rate in men, and a neutral association in women [22] [23]. Finally, a
study in a small group of patients with both diabetes and proteinuria
found a negative association between PA and survival rate [24]. To our
knowledge, this result has not been confirmed in any other study.
Each 2-h increase of TVwatching is associatedwith a 13% increase in
mortality rate [11]. Twenty three cohorts assessed SB, with 7 (30%)Fig. 1. Prima flow diagram. The literature search was conducted in two steps: a systematic review
Please cite this article as: Charansonney OL, et al, Physical activity: From
Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2013.11.012reporting results showing a negative association between SB and
survival rate in all but one study in California retirees. In the latter,
watching TV was associated with a lower mortality risk in younger
retired women and older men. Watching TV is neutral in the whole
cohort [25].
Randomized controlled trials generally failed to showa benefit of ex-
ercise training on mortality both in individual analyses and in meta-
analyses [10]. Interactions at the individual level between PF, PA, and
SB might partially explain these results. We will develop this point in
the next paragraph.
Interestingly, bothwalking velocity [12] and intensity of cycling [26]
are more powerfully related to mortality than the duration of either
activity.
From a physiological point of view, both high velocity walking and
cycling are conditioning PA which can significantly increase PF.of the literature between 2000 and November 1, 2011, and a follow-up search until now.
epidemiological evidence to individualized patient management, Int J
Table 3
Definitions and landmark values.
Energy expenditure (definition)
1 Kcal = 4.187 Joules (j)
Energy expenditure at rest 1 MET = 3.5 mlO2/min/kg =
0.018 Kcal/min/kg = 20.5 Watts
Burning 1 l O2 (glucid metabolism) 21 Kj or 0.005 Kcal
Spending 1 MET during one hour 1 MET/h
Sedentary behavior (examples)
b1.5 METS - Sitting time
- Car time
- Screen time
Levels of physical activity (examples)
Light 1.5–2.9 METS - Walking slowly
- Sitting
- Standing and performing light work
- Playing cards
- Fishing (sitting)
- Playing most musical instruments




- Golf (pulling clubs)
Vigorous N6 METS - Jogging, running
- Carrying heavy load
- Heavy farming
- Swimming (moderate to heavy)
Weekly energy expenditure for a man weighting 70 kg
Basal metabolism 168 MET-h = 14,000 Kcal
- Minimal recommended physical activity
(5 × 30 min moderate or 3 × 20 min
vigorous)
10 MET-h = 740 Kcal
- Most “Exercisers” (2 h/w)
- Cardiac rehabilitation (1.5 to 3 h/w)
Training for non-professional endurance
running (6 h at 11 km/h)
60 MET-h = 4400 Kcal
Active versus sedentary work 100 MET-h = 7400 Kcal
Amish adults (Labor-intensive farming) [30] 300 MET-h = 22,200 Kcal
Weekly energy “saving” with sedentary behaviors [24]
Obese versus lean sedentary behavior
(2 h less of standing and walking)
Minus 2500 Kcal = 34 MET-h
Sedentary versus active non-exercise
physical activity
Up to minus 7000 Kcal = 95 MET-h
4 O.L. Charansonney et al. / International Journal of Cardiology xxx (2013) xxx–xxx3.2. Statistically independent links do not imply a lack of interaction at an
individual's level
For instance, a very moderate PA in an individual with a low PF level
can increase compensatory SB. Conversely, after resuming regular PA a
previously active individual who has had to retrain his/her activity
after an injury can both improve his/her mood and decrease SB. In
fact, several pieces of epidemiological evidence suggest such
interactions.
The effect of work-related PA varies everywhere from worsening
impact on mortality [23] to improving the impact [27]. PA–SB interac-
tions might explain parts of these results. For instance, on one hand
perceived physical exertion at work can increase the risk of long term
sickness [28], but on the other hand, increasing the use of stairs at
work can improve an individual's risk profile [29]. This could be ex-
plained by the fact that high physical demand at workmay increase lei-
sure time SB and decrease PA. Both effects contribute to an individual's
increased mortality risk even if each component has too weak an effect
to influence adjusted correlation between work-related PA andmortal-
ity. Therefore, this link appeared to be independent from leisure time PAPlease cite this article as: Charansonney OL, et al, Physical activity: From
Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2013.11.012[23]. Increasing the use of stairs decreases SB at work and thereby de-
creases themortality risk. Furthermore, using stairs can increase PF [29].
Importantly, increasing PA with structured programs such as reha-
bilitation or sports can decrease unstructured PA [30] and increase SB,
contributing to the difficulty of demonstrating exercise-based
rehabilitation's benefit on mortality rate in randomized trials [30] [31].
3.3. An integrated individual-centric model describing the interrelation-
ships between PA, SB, PF, and premature mortality (Fig. 2)
The risk of premature mortality is strongly and inversely linked to
the physiological reserve of which PF is a major component.
SB and a low level of PA activate inappropriate stress responses
through mechanisms that we previously described (Fig. 3) [32]. These
mechanisms induce hypercoagulability, platelet hyperaggregability,
and chronic inflammation, eventually leading to chronic disease. Con-
versely, vigorous, high intensity PA can improve PF, thereby increasing
physiological reserve. This model can explain the non-linear relation-
ships between PA, PA components, and mortality. At one end of the
spectrum improvements in cardiovascular risk factors by high intensity
PA are mainly mediated by PF [33]. However, the benefit of a high level
of PF on mortality is unlikely to be mediated by traditional risk factors
[13] and we speculate that this benefit is mainly due to the high physi-
ological reserve in individuals with high PF. At the other end, a high per-
centage of sedentary time has been associated with a large, 3-fold,
increase in the risk of having metabolic syndrome [34]. Furthermore,
C-reactive protein explained 18% of the association between screen-
time and cardiovascular events [35]. Therefore, the risk associated
with a sedentary lifestyle appears mediated by cardiometabolic and in-
flammatory risk factors.
3.4. How various modalities of PA can influence mortality (Table 4)
A high intensity short duration of exercise increases PF; however, its
effect on overall PA might be very small if no other PA modality is asso-
ciated. For instance, 6 bouts of 0.5 min runs at 19 km/h each day (an un-
likely scenario) will increase weekly PA by less than 7 MET-h. In the
meantime, such high intensity PA could increase compensatory SB.
The benefit will probably be mainly associated with high PF and could
be mitigated by increased SB.
Conversely, long walks at low-moderate intensity can greatly in-
crease the volume of PA. For instance, walking 8 h/day at 2 km/h
(16 km/day) will increase weekly PA volume by 112 MET-h. Further-
more, daytime opportunities for SB will be reduced. Benefit will mainly
be associated with both increased PA volume and reduced SB.
Short walking activity at high speed will bring moderate beneficial
effects by increasing both PF and weekly PA volume with no or only
slight increase in SB. This level of activity corresponds to current recom-
mendations of 30 min of brisk walking at least five days per week.
4. Lifetime interactions between physical activity, physical fitness
and physiological reserve drive an individual's risk of mortality
Fig. 4 illustrates the lifetime interactions between PF, PA, and SB,
with trajectories for two hypothetical middle-aged men (~50 years
old at the beginning and weighing 70 kg). The first is a non-
professional competing athlete with a high PF level varying according
to training intensity. He is able to achieve a work load of 300 Watts
(15 METs) on a cycle-ergometer. Such a level of PF can be maintained
with 6 h of training per week, with energy expenditure up to 60
MET-h/week. However, plenty of time remains for SB (~160 h/week).
Despite his high level of PF, this individual can have both a highly seden-
tary lifestyle and a relatively low PA level. If this man has an active job
instead of a sedentary one, his daily energy expenditure can increase
by ~100 MET-h/week, far more than what he is spending during his
training [36]. Conversely, if he has a sedentary job and adopts SB, heepidemiological evidence to individualized patient management, Int J
Fig. 2. Interrelationships between physical activity, sedentary behavior, physical fitness, and individual’s risk of premature mortality. Left end of the spectrum: low physical activity (both du-
ration and intensity) leads to both high “opportunistic” sedentary behavior and low physical fitness, resulting in a highmortality risk. Right end: high physical activity intensity increases
physical fitness and physiological reserve, lowering mortality risk. This benefit is further increased by long physical activity duration and low sedentary behavior.
5O.L. Charansonney et al. / International Journal of Cardiology xxx (2013) xxx–xxxcan spend from 30 to 200 MET-h less per week! [36] Therefore, even a
high level of exercise training can be associated with a very significant
risk of premature mortality associated with both SB and low PA level.
The secondman can achieve a workload of 185Watts (9METs) on a
cycle-ergometer. He can perform any type of PA up to moderately high
physical exercise. Likemost exercisers heparticipates in exercise for less
than 2 h a week, spending less than 10 MET-h. He depends mainly on
non-exercise moderate PA to maintain his PF level (conditioning activ-
ities). His risk profile is driven by both his moderate PA [16] and his SB,
but also by his average PF which limits his physiological reserve. After
a first cardiovascular event (for example, acute ischemic event withFig. 3. Stress induced by a sedentary lifestyle. Sedentary behavior induces chronic and severe imm
tance and atrophy of the muscles, induces inappropriate energy reallocation towards central
chronic inflammation (Charansonney and Després, 2010).
Please cite this article as: Charansonney OL, et al, Physical activity: From
Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2013.11.012cardiac failure) his PF level sharply decreases and only partly recovers
with treatment, including drugs and rehabilitation (generally 1.5 to
3 h/week in 3 to 5 sessions), which might increase energy expenditure
by up to 10 MET-h/week (5 sessions of 40 min at 70% of CRF). Rehabil-
itation can slightly improve PF butwithout proven significant impact on
mortality [31]. As previously mentioned, an increase in SB and/or a
decrease in non-exercise PA during a rehabilitation programcan jeopar-
dize the benefit of exercise training. Despite partial recovery, he remains
short of breath duringmoderate PA (NYHA class 2). A subsequent event
(heart failure) further decreases his PF, impairing his ability to perform
even daily activity (NYHA class 3) and leads to a state of frailty [37] [38].obilization. The stress response triggered by immobilization increases both insulin resis-
adipocytes, and, eventually, leads to hypercoagulability, platelet hyperaggregability and
epidemiological evidence to individualized patient management, Int J
Table 4







High intensity, short duration +++ + +/−
Low intensity, very long duration (walking all day) NE +++ −−
Moderate intensity, moderate duration + ++ +/−
PA: physical activity, PF: physical fitness, SB: sedentary behavior.
+++: strong increase,++:moderate increase,+:modest increase,−−: decrease;+/−
: possible increase or decrease, NE: no effect.
6 O.L. Charansonney et al. / International Journal of Cardiology xxx (2013) xxx–xxx5. Clinical management of individuals: promoting PA should have
the highest priority
5.1. A key step is to identify the barriers to PA
Lack of time is frequently brought forward. Emphasis on the useful-
ness of non-exercise PA such as walking to work or using stairs can help
overcome this objection. Health conditions are often considered a barri-
er by elderly individuals. Osteoarthritis, back pain, and dizziness are
among the most common. Lack of interest, lack of company, spouse's
condition, fatigue, or depression also often limits PA. It should be strong-
ly emphasized that almost all of the health conditions perceived as a
barrier to PA can be improved by PA. Furthermore, conditions such
as depression contribute to low treatment compliance, whatever the
treatment is.
5.2. Improving treatment choice to increase PA
In a significant number of cases, management of inhibiting condi-
tions such as osteoarticular pain, or depression, might have the highest
priority over other treatments.When applying this approach, treatment
choice and dose optimization should be driven by the drug's side effects
on the individual and not by the drug's statistically defined target dose.
On one hand, higher doses of statin seem to have a larger benefit for
preventing cardiovascular events but have no unequivocally significant
effect on mortality [39]. On the other hand, statins can induce
dose-dependent muscle pain, and can increase susceptibility to
exercise-induced muscle injury, so higher doses of statin may limit PAFig. 4. Hypothetical trajectories of middle-age men. Blue curve - maximal physical capacity of a 50-y
intensity training (variation according to training periods). Slow physiological decrease of physica
with sedentary behavior and who exercise 2 h/week. Physical capacity is strongly impacted by ca
restored by exercise rehabilitation. Accelerated degradation of physical capacity follows, leading
death. NYHA: New York Health Association class 2: dyspnea during moderate physical activity, cl
Please cite this article as: Charansonney OL, et al, Physical activity: From
Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2013.11.012and increase compensatory SB [40]. Therefore, since both a low level
of PA [16] and a higher level of SB [11] are associated with an increased
risk of premature mortality, the dose of statin should be adjusted for
each individual so that the highest possible PA level can be achieved
(Fig. 5) [41] [42]. Furthermore, we should ensure that drug-induced
symptoms do not impair the efficacy of exercise-based rehabilitation,
since rehabilitation may decrease the risk of mortality in individuals
with coronary heart disease [17]. It is possible that beta-blockers
may also limit exercise tolerance in some individuals: however,
beta-blockers greatly improve survival in patients with heart failure,
and have an almost neutral effect on exercise capacity. Indeed, a
meta-analysis of randomized controlled trials found that beta-blockers'
benefit on mortality in patients with heart failure is related to patient
heart rate, not to beta-blocker dose [43]. Therefore, beta-blocker dose
optimization should be based on an individual's heart rate and his/her
tolerance of such factors as dizziness, fatigue, and hypotension [44].
Not surprisingly, beta-blocker mean doses used in real life cohorts of el-
derly patients with heart failure tend to be lower than the doses used in
randomized trial cohorts of usually younger patients with fewer
comorbidities.
Screening, diagnosis, and optimal management of sleep apnea are
also critical to limiting day-time fatigue, sleepiness, and induced SB.
Similarly, the use of psychotropic drugs for treatment of insomnia, anx-
iety, or depression should carefully avoid side effects impairing PA and
promoting SB (sleepiness, orthostatic hypotension …). Table 5 lists
some commonly prescribed drugs whose side effects can impair PA.
Rehabilitation programs focused on improving gait, osteoarticular or
cardiovascular conditions can be used to break the vicious cycle of
health-barrier-to-physical-activity and SB.
6. Discussion
Our model is established on strong epidemiological associations be-
tween PA, PF, SB, and premature mortality rate. These associations are
found in both men and women, in patients of many age-classes, with
various disease conditions and with various cultural backgrounds.
However, the lack of consistent effect of rehabilitation, e.g. systematic
increase of PF, on mortality in randomized controlled trials preclude
definite conclusion on the causation between PF and mortality. Still,ear old non-professional endurance athlete: high level of physical fitness depending on high
l capacity with aging. Red - curve: maximal physical capacity of a “healthy” 50-year old man
rdiovascular events (e.g. heart failure after myocardial infarction) and could incompletely be
to frailty, when physical capacity is just able to sustain sedentary behavior, and, eventually,
ass 3: dyspnea during daily activity (based on Buchner, 1992 and Charansonney, 2011).
epidemiological evidence to individualized patient management, Int J
Fig. 5. Benefit/risk of statin in patient with coronary heart disease. The benefit of increasing the dose of statin should be balanced against the risk of inducing muscle pain and of limiting
physical activity.
7O.L. Charansonney et al. / International Journal of Cardiology xxx (2013) xxx–xxxour model suggests that interactions at the level of the individual be-
tween PF, PA, and SB might explain non-conclusive clinical trial results.
This is physiologically plausible. New clinical trials should specifically
analyze interactions between PF, PA, SB, and intervention at the individ-
ual level to test this hypothesis.
One limit of our model is the lack of quantitative estimation of
absolute mortality risk. PF can be objectively measured. However,
there is a need for determining normative PF levels in large and repre-
sentative population samples [45]. PA and SB, both behaviors, are far
more difficult to measure and may be highly influenced by the socio-Table 5
Potential impact on physical activity of drugs commonly prescribed to patients with cardiovas
Class of drugs Expected therapeutic benefit Side eff











ACE inhibitors Improve survival in HT and HF Hypote
Cough
Angiotensin II receptor antagonists Improve survival in HF, Decrease
blood pressure
Hypote
Calcium antagonists Improve survival in HT Hypote
Aldosterone antagonists Improve survival in HF, Decrease
blood pressure
Sleepin
Statins Improve survival Muscle
Metformin T2DM (blood glucose control) Gastroi
Insulins DM (blood glucose control) Weight
Need fo
Sulfonyl ureas T2DM (blood glucose control) Hypogl
DPP4 inhibitors T2DM (blood glucose control)
GLP-1 agonists T2DM (blood glucose control) Weight
Injectab
Aspirin Improve survival Hemato
P2Y12 inhibitors Improve survival Hemato
Anti-vitamin K Decrease risk of stroke (AF) Hemato
New oral anticoagulants Decrease risk of stroke (AF) Hemato
SSR inhibitors Treat depression symptoms Astheni
AF: Atrial fibrillation; HF: Heart failure; HT: Hypertension; PA: Physical activity; T2DM: Diabet
Please cite this article as: Charansonney OL, et al, Physical activity: From
Cardiol (2013), http://dx.doi.org/10.1016/j.ijcard.2013.11.012cultural environment. Despite these limitations, we think that available
data could be integrated with a semi-quantitative approach, such as the
one used in our model, in order to help patient management.
The absence of randomized trial positive results weakens the
estimation of PA/PF's increased benefit compared with drug efficacy.
Therefore, benefit/risk ratio comparisons such as the one shown in
Fig. 5 can be challenged. Statin benefit onmortality has not beenunequiv-
ocally established [39]. Furthermore, some large controlled trials evaluat-
ing the effect of different statin doses only included a small percentage of
the eligible population [46]. Therefore, established benefits of highlycular disease.
ects impacting PA Potential mechanisms
eart rate reserve Limit adaptation to exercise
gain (atenolol, ASCOT) Limit non-exercise PA (increase weight)
effect on lipid and glucid metabolism Increase risk of fall (hypotension)
ss, asthenia, bronchospasm Limit outdoor activities (gait instability)
effect on lipid metabolism Limit outdoor activities (diuresis)
Sleep disturbance (diuresis)
e diuresis and micturition. Increase risk of fall (hypotension)
atic hypotension
nsion Increase risk of fall (hypotension)
Sleep disturbance (cough)
nsion Increase risk of fall (hypotension)
nsion, leg swelling Increase risk of fall (hypotension)
Pain in the legs
ess, gastrointestinal Sleepiness
injury Limit exercise (muscle pain)
Sleep disturbance (muscle pain)
ntestinal Limit outdoor activities (GI)
gain, hypoglycemia Limit outdoor activities
r glucose monitoring Increase risk of fall (hypoglycemia)
Limit autonomy (injection and blood
glucose monitoring)
ycemia Increase risk of fall (hypoglycemia)
loss, nausea Improve physical well-being
le
ma Limit type of exercise (trauma)
ma Limit type of exercise (trauma)
ma Limit type of exercise (trauma)
Limit autonomy (blood test monitoring)
ma Limit type of exercise (trauma)
a, weight gain, sleepiness, dizziness Limit non-exercise physical activity
Increase risk of fall (dizziness)
es mellitus (type 2).
epidemiological evidence to individualized patient management, Int J
8 O.L. Charansonney et al. / International Journal of Cardiology xxx (2013) xxx–xxxstudied drugs such as statins have often limited validity especially in
populations usually excluded from clinical trials, such as elderly with
co-morbidities. Given these limitations for both PA/PF interventions and
drugs' therapeutic benefits we think that a comparative approach using
the existing data is legitimate and can improve patient management.
7. Conclusion
The sedentary life style syndrome is the result of three relatively
independent factors: a low or decreasing PF, a low level of PA and a high
level of SB. These three components should be considered together when
designingpublic healthpolicies ormanaging individual patients.Otherwise,
the benefit obtained in improving one of these factors (e.g. exercise-related
PA) can be counterbalanced by negative impact on the others (e.g. decreas-
ing non-exercise PA and increasing SB). The impact of drug treatments on
PA and SB should be carefully assessed both whenmanaging an individual
patient and, ideally, when evaluating treatment strategies including those
strategies to be used in drug development studies.
The beauty of giving the fight against sedentary lifestyle all its
deserved consideration is that it brings a clear and simple way of prior-
itizing both drug and non-drug treatment strategies, enabling us to
choose drugs for optimizing benefit/risk ratio on an individual basis.
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